Metastatic Prostate Cancer
Conditions
Brief summary
The objective of this study is to evaluate a radiolabeled urea-based small molecule inhibitor of prostate-specific membrane antigen (PSMA), \[18F\]DCFPyL (DCFPyL) PET/CT (or PET/MRI imaging if available) for detection of metastatic prostate cancer. PSMA is a well characterized histological marker of prostate cancer tumor aggressiveness and metastatic potential. Preliminary first-in-human studies demonstrate high specific uptake of a first generation less avid compound, DCFBC, in metastatic prostate cancer and demonstrated feasibility for prostate cancer metastatic detection. Investigators propose to assess the ability of DCFPyL PET to detect metastatic prostate cancer by visual qualitative and quantitative SUV analysis. Correlation will be made to sites of suspected metastatic disease detected by ultra sensitive but less specific \[18F\]Sodium Fluoride (NaF)-PET/CT imaging for prostate cancer.
Interventions
DRUG18F-NaF
Sponsors
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Histological confirmation of prostate cancer 2. Radiologic evidence of new or progressive metastatic disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), bone scintigraphy, \[18F\]Sodium Fluoride PET, and/or \[18F\]FDG PET 3. Rising PSA on two observations taken at least 1 week apart 4. Adequate peripheral venous access or available central venous catheter access for radiopharmaceutical administration 5. Patient can remain on androgen deprivation therapy if on the same regimen prior to documentation of progressive metastatic disease 6. Patient cannot start a new therapy for prostate cancer prior to study radiopharmaceutical imaging 7. Patient is judged by the Investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits 8. Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures
Exclusion criteria
1. Patient has been treated with an investigational drug, investigational biologic, or investigational therapeutic device within 14 days prior to study radiotracer administration 2. Prior radiation therapy, chemotherapy, or androgen-deprivation therapy within 2 weeks prior to study radiotracer administration (Washout is one half-life of the drug or 2 weeks, whichever is longest) 3. Initiation of new therapy for progressive metastatic disease since radiographic documentation of progression. 4. Serum creatinine \> 3 times the upper limit of normal 5. Total bilirubin \> 3 times the upper limit of normal 6. Liver Transaminases \> 5times the upper limit of normal 7. Unable to lie flat during or tolerate PET/CT (or PET/MRI imaging if available) 8. Prior history of any other malignancy within last 2 years, other than skin basal cell carcinoma or superficial bladder cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of DCFPyL- PET/CT (or PET/MRI imaging) to NaF-PET/CT | 4 years | Compare the diagnostic accuracy during visit 2 18F-DCFPyL imaging and visit 3 NaF imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimation of new or progressive metastatic lesions found on NaF and 18F-DCFPyL | 4 years | Compare proportion of new or progressive metastatic lesions found on NaF-PET/CT that are DCFPyL- PET/CT (or PET/MRI imaging if available) positive, and vice-versa. |
Countries
United States
Outcome results
None listed